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osmotic solutions elicit sensory reflexes, including cough, and
are a potent stimulus for airway narrowing in asthmatic
patients, but the mechanisms involved are not known. Transient
receptor potential cation channel, subfamily V, member 4
(TRPV4) is widely expressed in the respiratory tract, but its role
as a peripheral nociceptor has not been explored.
Objective: We hypothesized that TRPV4 is expressed on airway
afferents and is a keyosmosensor initiating reflexevents in the lung.
Methods: We used guinea pig primary cells, tissue bioassay,
in vivo electrophysiology, and a guinea pig conscious cough
model to investigate a role for TRPV4 in mediating sensory
nerve activation in vagal afferents and the possible downstream
signaling mechanisms. Human vagus nerve was used to confirm
key observations in animal tissues.
Results: Here we show TRPV4-induced activation of guinea pig
airway–specific primary nodose ganglion cells. TRPV4 ligands
and hypo-osmotic solutions caused depolarization of murine,
guinea pig, and human vagus and firing of Ad-fibers (not C-
fibers), which was inhibited by TRPV4 and P2X3 receptor
antagonists. Both antagonists blocked TRPV4-induced cough.
Conclusion: This study identifies the TRPV4-ATP-P2X3
interaction as a key osmosensing pathway involved in airway
sensory nerve reflexes. The absence of TRPV4-ATP–mediated
effects on C-fibers indicates a distinct neurobiology for this ion
channel and implicates TRPV4 as a novel therapeutic target for
neuronal hyperresponsiveness in the airways and symptoms,
such as cough. (J Allergy Clin Immunol 2016;138:249-61.)
Key words: Transient receptor potential, sensory nerves, vagus,
cough, ion channels, hypotonicity, ATP
Sensory nerves innervating the airways play an important
role in regulating various cardiopulmonary functions, maintain-
ing homeostasis under healthy conditions, and contributing to
pathophysiology in disease conditions. Transient receptor
potential (TRP) channels are a family of cation channels that
are activated by a large number of diverse stimuli, including
temperature, pH, and osmolarity.1 TRPA1 and TRPV1 ion
channels expressed on peripheral nociceptors act as sensory
transducers for chemosensitive stimuli, temperature, and pH.
They have also been demonstrated to be involved in initiating
the reflex bronchospasm that defines the late asthmatic
response2 and cough in human subjects and animal models.3-6249
J ALLERGY CLIN IMMUNOL
JULY 2016
250 BONVINI ET ALAbbreviations usedAUC: Area under the curve[Ca21]i: Intracellular free calciumCOPD: Chronic obstructive pulmonary diseaseCV: Conduction velocityDiI: 1,19-Dioctacetyl-3,3,39,39-tetramethylindocarbocyanine
perchlorateDMSO: Dimethyl sulfoxideECS: Extracellular solutionK50: 50 mmol/L Potassium chloride solutionab-MeATP: ab-Methylene-ATPNCBI: National Center for Biotechnology Information4a-PDD: 4a Phorbol 12,13-didecanoatePx1: Pannexin 1RAR: Rapidly adapting stretch receptorTRP: Transient receptor potentialTRPV4: Transient receptor potential cation channel, subfamily V,
member 4Hypo-osmotic solutions have been shown to elicit sensory
reflexes, including cough,7 and are a potent stimulus for airway
narrowing in asthmatic patients,8,9 and airway surface fluid
composition appears to become more hypotonic in asthmatic pa-
tients.10 However, the sensory transduction mechanisms involved
in regulating reflexes in response to changes in osmolarity are not
known.
Transient receptor potential cation channel, subfamily V,
member 4 (TRPV4) is a polymodal gated TRP channel that is
activated by a diverse range of stimuli, including acidic pH,
temperature, mechanical stress, the synthetic phorbol ester 4a
phorbol 12,13-didecanoate (4a-PDD), and arachidonic acid
metabolites (epoxyeicosatrienoic acids).11 TRPV4 can also be
activated in the cellular response to hypotonicity, suggesting it
might be an osmosensor, and sensing of osmotic changes by
nociceptors is reduced in Trpv42/2 mice and in rats treated with
TRPV4 blockers or TRPV4 anti-sense small interfering
RNA.12,13 TRPV4 is widely expressed in the respiratory tract,
including the epithelium (human), macrophages (human and
murine), and airway smooth muscle (human and guinea
pig).14-17 Furthermore, polymorphisms in the TRPV4 gene are
associated with chronic obstructive pulmonary disease (COPD)
phenotypes.18 However, limited information is available
regarding TRPV4 expression in peripheral nociceptive neurons
and in particular those that innervate the lung.
Using calcium imaging techniques, in vivo electrophysiology, an
in vivo animal model of cough, and human, guinea pig, and murine
bioassays, we have identified a TRPV4-ATP-P2X3 signaling
pathway as a key driver of hypotonicity-induced activation
of airway afferents. In vivo single-fiber electrophysiologic
experiments demonstrated that both a TRPV4 agonist and a
hypo-osmotic solution caused a marked and prolonged stimulation
of all of the Ad-fibers examined (both capsaicin-sensitive and
insensitive fibers) but had no effect on C-fibers. Unlike the
activation of fibers observed with capsaicin and citric acid, which
occurred rapidly, activation caused by a TRPV4 ligand was
relatively slow, which indicated an indirect mechanism of action.
All the TRPV4-mediated effects were inhibited in the presence
of a P2X3 antagonist, indicating a role for ATP. It has previously
been demonstrated that ATP release from hypotonically or
TRPV4-stimulated airway epithelial cells involves Rho-regulatedopening of pannexin 1 channels,19 and we have shown this same
mechanism to be operative in the TRPV4-induced activation of
vagal afferents. The role of ATP in TRPV4 signaling in peripheral
Ad nociceptors is a novel finding, and the absence of TRPV4-ATP–
mediated effects on C-fibers provides a distinct neurobiology for
this ion channel compared with TRPV1 and TRPA1.METHODS
Additional information can be found in theMethods section in this article’s
Online Repository at www.jacionline.org.Animals
Male Dunkin-Hartley guinea pigs (300-500 g; 400-800 g for single-fiber
in vivo studies) and C57BL/6 mice (18-20 g) were purchased from Harlan
(Bicester, Oxon, United Kingdom) or B&K (Hull, United Kingdom) and
housed in temperature-controlled (218C) rooms with food and water
freely available for at least 1 week before commencing experimentation.
Homozygous breeding pairs of mice genetically modified to disrupt the
TRPV4 gene (Trpv42/2) or the pannexin 1 gene (Px12/2) were used.
Experiments were performed in accordance with the UK Home Office
guidelines for animal welfare based on the Animals (Scientific Procedures)
Act of 1986 and the ARRIVE guidelines.20Isolated primary airway specific vagal neurons
Cell dissociation. Guinea pigs were killed by means of injection of
sodium pentobarbitone (200 mg/kg administered intraperitoneally). Nodose
and jugular ganglia were dissected free of adhering connective tissue,
and neurons were isolated by means of enzymatic digestion, as described
previously.21,22
Calcium imaging. Intracellular free calcium ([Ca21]i)measurements
were performed in dissociated nodose and jugular neurons and
neurons projecting fibers specifically to the airways, which were identified as
previously described.21,22 The concentration-response data represent an
overview of responding cells only. The criteria for a ‘‘responsive cell’’ was
judged as an increase in [Ca21]i of 10% or greater of the response to
50 mmol/L potassium chloride solution (K50). In each case N is defined as the
number of animals, and n is defined as the number of cells tested.
Single-cell RT-PCR. Isolated nodose- and jugular-derived neurons
harvested from male Dunkin-Hartley guinea pigs were placed in a Petri
dish containing extracellular solution (ECS), and airway terminating
(1,19-dioctacetyl-3,3,39,39-tetramethylindocarbocyanine perchlorate [DiI]–
stained) neurons were identified by using a Widefield Microscope (Olympus
IX-71 inverted microscope; Olympus, Center Valley, Pa). Selected individual
neurons were carefully harvested by using suction into the end of a
custom-made glass micropipette (tip ID, 50-70 mm; OD, 2 mm; FIVEphoton
Biochemicals, San Diego, Calif) manipulated into place by using a
micromanipulator (Three-axis Water Hydraulic Micromanipulator MHW3;
Narishige, Tokyo, Japan). The micropipette tip was then broken into a
microreaction tube containing 1 mL of RNaseOUT (Life Technologies, Grand
Island, NY) and placed on ice. Protocols for DNA digestion, cDNA synthesis,
and PCR of selected targets were carried out based on the methodology
described by Kwong et al.23 Single-cell PCR primer information can be found
in Table E1 in this article’s Online Repository at www.jacionline.org.
Isolated vagus nerve preparation. Guinea pigs and mice
(C57BL/6 or Trpv42/2)24,25 were killed by means of injection of sodium
pentobarbitone (200 mg/kg administered intraperitoneally). The vagus nerves
were removed, and experiments were conducted in a fully characterized
isolated vagus nerve preparation, as described in previous publications.5,26
Human vagus nerve sections (n 5 6, 38- to 57-year-old male donors and
38- to 68-year-old female donors with no known respiratory disease)
were obtained from the International Institute for the Advancement of
Medicine (Edison, NJ), and in all cases consent was granted for use in
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Harefield Trust.
In vivo single-fiber preparation. Guinea pigs were anesthe-
tized with urethane (1.5 g/kg) intraperitoneally. If required, anesthesia was
supplemented with additional urethane. The trachea was cannulated with a
short length of Portex tubing (Fisher Scientific UK Ltd, Loughborough,
United Kingdom), and blood gases and pH were maintained at physiologic
levels by means of artificial ventilation (small-animal ventilator; Ugo Basile,
Varese, Italy), with a tidal volume of 10 mL/kg and 50 to 60 breaths/min of
laboratory air. The right jugular vein and carotid artery (passed to the
ascending aorta/aortic arch) were cannulated for injecting drugs and
measuring systemic arterial blood pressure, respectively. Tracheal pressure
was measured with an air pressure transducer (SenSym 647, Farnell, United
Kingdom) connected to a sidearm of the tracheal cannula. Animals were
paralyzed with vecuronium bromide, which was initially administered at a
dose of 0.10 mg/kg intravenously, followed every 20 minutes by 0.05 mg/kg
administered intravenously to maintain paralysis. Both cervical vagus nerves
were located through a cervical incision and dissected free from the carotid
artery and sympathetic and aortic nerves, and the nerves were cut at the central
end. The left vagus nerve was used for sensory nerve fiber recording, as
previously described.27
Single vagus nerve fibers were identified as originating from the major
groups of airway sensory nerve endings (ie, slowly adapting stretch receptors,
rapidly adapting stretch receptors [RARs], irritant receptors, and Ad-fibers),
which were further subdivided into those that were more acid and/or less
capsaicin sensitive and with conduction velocities (CVs) slower than those of
conventional RARs, and pulmonary/bronchial C-fiber receptors by using
several criteria.27 These include pattern of spontaneous discharge, response to
hyperinflation and deflation, adaptation indices, response to capsaicin/citric
acid administration, and CVs. As a rule, a receptor that had no obvious pattern
to the spontaneous activity (often very sparse) and did not respond to hyperin-
flation/hyperdeflation but did respond to capsaicin aerosol was pursued as a C-
fiber. Alternatively, and in the first instance, a receptor that had a spontaneous
discharge with a definite rhythmic respiratory pattern and adapted rapidly/var-
iably to hyperinflation/deflation was pursed as an Ad-fiber. Finally, verification
of fiber type was confirmed at the end of the experiment by determining the CV.
Conscious guinea pig cough model. In all experiments the
operator was blind to the treatment group. Conscious unrestrained guinea pigs
were placed in individual plastic, transparent, whole-body plethysmograph
chambers (Buxco, Wilmington, NC), and cough was detected, as previously
described.5,26
Details on compounds andmaterials can be found in theMethods section in
this article’s Online Repository.
Data analysis and statistics
The area under the curve (AUC) of calcium signal (calcium flux: total
increase in calcium level to greater than the resting level over time)was used to
measure primary neuron responses, which were normalized to calcium flux
generated by application of K50. Inhibition of agonist-induced responses was
analyzed by using an unpaired t test comparing theK50 percentage (AUC)with
and without an antagonist. Data were analyzed for responding cells only,
which were defined as a neuron with a response of 10% or greater K50,
and are presented as means 6 SEMs, where N indicates the number
of animals and n indicates the number of cells. Inhibition of agonist-
induced responses in the isolated vagus nerve preparation were analyzed
by using a 2-tailed paired t test, comparing responses to agonist in the
absence and presence of antagonist in the same piece of nerve. Data are
presented as means 6 SEMs, with statistical significance set at a P value of
less than .05.
In the single-fiber experiments data were analyzed by using the paired t test
to compare responses (absolute values) after stimulus with baseline values
immediately preceding the response. Data are presented as means 6 SEMs,
with statistical significance set at a P value of less than .05.
Inhibition of fiber firing was analyzed by using a paired t test to
compare responses after antagonist with control values before antagonist
administration or using an unpaired t test comparing responses to vehiclecontrol as appropriate. Statistical significance was set at a P value of
less than .05.
Inhibition of cough by the TRPV4 antagonist or the P2X3 receptor
antagonist in vivowas analyzed by using theMann-WhitneyU test to compare
responses from the antagonist groupwith those from the vehicle control group.
Data are presented as means 6 SEMs, with statistical significance set at a
P value of less than .05.RESULTS
Effect of TRPV4 agonists on airway-stained vagal
ganglia neurons
To assess the airway-specific effects of TRPV4 stimulation, we
used fluorescent imaging to investigate the effects of
GSK1016790A (TRPV4 agonist28) on isolated neurons from
the guinea pig vagal ganglia, which were labeled with the retro-
grade tracer DiI (Fig 1, A). GSK1016790A induced a slow
concentration-dependent increase in [Ca21]i levels in nodose
(Fig 1, B and C) but not jugular neurons (Fig 1, D). Maximum
[Ca21]i signals for the responsive nodose neurons (expressed as
a percentage of K50 AUC) were 132% 6 50% at 300 nmol/L
(Fig 1,C). There were a total of 36 airway nodose cells examined,
of which 75% responded to GSK1016790A, and 34 jugular
airway cells, of which only 12% were responsive to
GSK1016790A stimulation (Fig 1, D). A similar pattern was
seen in nonairway neurons: of a total of 58 nonairway
nodose neuronal cells, 52% were responsive, and of the 46
nonairway jugular neurons, 20% responded to GSK1016790A
stimulation.Effect of TRPV4 agonists on vagal sensory afferents
TRPV4 agonists (GSK1016790A and 4a-PDD29) induced
concentration-dependent depolarization (a measure of nerve
activation) of guinea pig (Fig 2,A andB) andmouse vagal sensory
nerves (Fig 2, D and E), reaching a maximum of approximately
50% to 70% of the control capsaicin response. Hypo-osmotic
solution also caused an osmotic strength-dependent
depolarization in both the guinea pig (Fig 2, C) and mouse
(Fig 2, F) vagus nerve. Because of the limited availability of
human vagus nerve, only key experiments were performed.
Submaximal concentrations of GSK1016790A (300 nmol/L),
4a-PDD (1 mmol/L), and hypo-osmotic solution (280 mOsm),
which were effective in the guinea pig and mouse vagus, were
tested on isolated human vagus nerve and induced nerve
depolarization (Fig 2, G).
HC067047 (TRPV4 antagonist30) concentration-dependently
inhibited GSK1016790A (300 nmol/L)–induced depolarization
of guinea pig (Fig 3, A) and mouse (Fig 3, D) vagus. The
concentration of HC067047 (10 mmol/L) producing the
greatest inhibition of GSK1016790A (Fig 3, A) also inhibited
depolarization evoked by 4a-PDD (1 mmol/L) and hypo-
osmotic solution (280 mOsm) in guinea pig (Fig 3, B and C,
respectively) and mouse vagus nerve (Fig 3, E and F,
respectively). Another TRPV4 antagonist, GSK2193874,31 also
inhibited GSK1016790A (300 nmol/L)–induced depolarization
in a concentration-dependent manner in guinea pig vagus with a
similar potency to HC067047 (see Fig E1 in this article’s Online
Repository at www.jacionline.org). Neither GSK2193874
(10 mmol/L) nor HC067047 (10 mmol/L) had any effect on
capsaicin- or acrolein-induced depolarization in guinea pig or
mouse vagus (see Fig E2 in this article’s Online Repository at
FIG 1. A and B, Bright-field and pseudocolor images of an airway-specific neuron stained with the
retrograde tracer DiI (Fig 1, A) and the same neuron exposed to GSK1016790A (100 nmol/L) showing a
[Ca21]i level increase, with the right-hand side indicating images taken during real-time recording (Fig 1,
B). C and D, Effect of GSK1016790A on [Ca21]i levels in DiI-stained neurons for responsive-only nodose
(Fig 1, C) and jugular neurons (Fig 1, D). Data are presented as means 6 SEMs of 4 to 11 observations
and 4 to 6 guinea pigs. *Statistical significance (P < .05) compared with relevant control.
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GSK1016790A, 4a-PDD, and hypo-osmotic solution was
reduced in Trpv42/2 mice, whereas responses to TRPV1
(capsaicin) and TRPA1 (acrolein) agonists were unaffected
(Fig 3, G). Genetic knockdown of the murine TRPV4 gene in
the Trpv42/2 colony was verified by means of genotyping.
Finally, the TRPV4 antagonist (HC067047) inhibited
depolarization evoked by GSK1016790A, 4a-PDD, and hypoto-
nicity in human vagus (Fig 3, H and I).Effect of TRPV4 agonists on action potential firing
in guinea pig Ad-fibers
When administered by means of aerosol to anesthetized guinea
pigs, capsaicin (100 mmol/L for 15 seconds) activated 2 of the 3
Ad-fibers (CV range, 2.3-7.14 m/s) and all 5 of the C-fibers (CV
range, 0.57-0.92 m/s; could not distinguish between bronchial or
pulmonary C-fibers) examined. Capsaicin also evoked broncho-
constriction in all guinea pigs examined, which was preceded by
activation of the fiber under examination (except for 1 Ad fiber).
FIG 2. A-F, Effect of vehicle (0.1% DMSO), the TRPV4 agonists GSK1016790A and 4-aPDD, and hypo-
osmotic solution on the activation of guinea pig (Fig 2, A-C) and mouse (Fig 2, D-F) isolated vagus nerve
compared with capsaicin as a reference (n 5 4-6). G, Activation of human vagus nerve by GSK1016790A
(300 nmol/L), 4a-PDD (1 mmol/L), and280 mOsm (n5 3). Data are presented as means6 SEMs. *Statistical
significance (P < .05) compared with relevant control.
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examined (Fig 4, B and C). In contrast to capsaicin, citric acid did
not cause bronchoconstriction. Aerosol administration of
GSK1016790A (10 mg/mL) caused a marked prolonged stimula-
tion of all of the Ad-fibers examined (ie, total impulses increased
from 15.36 8.7 to 48546 3708; n5 3) but had no effect on the
C-fibers (Fig 4, A-C). Unlike the activation of Ad-fibers observed
with capsaicin and citric acid, which occurred within 35 seconds
of administration, that caused by GSK1016790A did not
commence until 101.5 6 21.2 seconds. In addition, although
the activation of Ad-fibers lasted no longer than 3.5 to 4.0 minutes
after capsaicin and citric acid, the fibers were still firing vigor-
ously at 30 minutes after GSK1016790A (Fig 4, A).
GSK1016790A also caused marked bronchoconstriction with
a slow onset and prolonged duration, which ensued after the
Ad-fibers had been activated. Vehicle administration alone had
no effects on the firing of either the Ad- or C-fibers examined.
In an independent series of experiments to examine the effects
of hypo-osmotic solutions, 4 separate Ad-fibers (CV range,
4.7-11.3 m/s) and 3 C-fibers (CV range, 0.47-0.85 m/s) were
used. Capsaicin activated 2 of the 4 Ad-fibers and the 3 C-fibers,
whereas citric acid activated all fibers. Similar to GSK1016790A,
aerosol administration of hypo-osmotic solution (280 mOsm)caused stimulation of all of the Ad-fibers examined: total
impulses increased from 10.33 6 2.7 to 203.7 6 24.5 (n 5 3,
P < .05) but had no effect on C-fibers (Fig 4, D and E). Control
isosmotic solution administration alone had no effect on the firing
of either the Ad- or C-fibers examined.Mechanism involved in TRPV4-induced activation
of airway sensory nerves
To determine whether TRPV4, P2X2, and P2X3 were
expressed in individual neurons, single-cell RT-PCR was carried
out on isolated airway terminating nodose and jugular neurons.
TRPV4was not expressed in any of the jugular neurons examined
(0/30 cells) but was expressed in 1 of 32 nodose neurons. P2X2
(without P2X3 coexpression) was expressed in 0 of 30 jugular
neurons and 2 of 32 nodose neurons. P2X3 (without P2X2
coexpression) was expressed in 22 of 30 jugular neurons and 6 of
32 nodose neurons. P2X2 and P2X3 were coexpressed in 1 of 30
jugular neurons and 11 of 32 of nodose neurons. Of interest, the
single nodose TRPV4-positive cell coexpressed P2X2 (but not
P2X3). Incidentally, the 1 neuron identified as positive for TRPV4
was confirmed after a second assay using the same primers,
indicating the possibility that TRPV4 is expressed on sensory
FIG 3. A-F, H, and I, Effect of the TRPV4 antagonist (HC067047) on either the TRPV4 agonists GSK1016790A
(300 nmol/L)– or 4a-PDD (1 mmol/L)–induced or hypo-osmotic solution (–80 mOsm)–induced depolarization
of guinea pig (Fig 3, A-C; n 5 4-6), mouse (Fig 3, D-F; n 5 4-6), and human (Fig 3, H) isolated vagus nerve
(n 5 2-3; example trace is shown in Fig 3, I). G, Depolarization of the vagus from Trpv42/2 and wild-type
(WT) control mice to GSK1016790A (300 nmol/L), 4a-PDD (1 mmol/L), hypo-osmotic solution
(280 mOsm), capsaicin (1 mmol/L), and acrolein (300 mmol/L; n 5 4-6). Data are presented as
means 6 SEMs. *Statistical significance (P < .05) compared with relevant control.
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FIG 4. A, Trace indicates changes in tracheal pressure (top) and action potential firing (bottom) of Ad- and
C-fibers in response to GSK1016790A (10 mg/mL). B and C, Total impulses were significantly increased after
application of citric acid (CA; 0.3 mol/L) and GSK1016790A (10 mg/mL) in Ad-fibers (Fig 4, B), but only
capsaicin (Caps; 100 mmol/L) and citric acid (0.3 mol/L) significantly increased firing in C-fibers (Fig 4, C).
D and E, Hypo-osmotic solution (280 mOsm) significantly increased total impulses in Ad-fibers but had
no effect on C-fibers (Fig 4, D and E, respectively). Data are presented as means 6 SEMs of 3 or 4
observations. Veh, Vehicle. *Statistical significance (P < .05), paired t test comparing responses before
and after aerosol administration of agonist.
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FIG 5. A and B, ab-MeATP (10 mmol/L) caused an increase in [Ca21]i levels predominantly from guinea pig
airway–specific nodose ganglion neurons (Fig 5, A) and a concentration-dependent depolarization of the
guinea pig vagus nerve (Fig 5, B). C and D, This response was inhibited by the P2X3 antagonists AF-353
(10 mmol/L) and TNP-ATP (10 mmol/L) in both guinea pig (Fig 5, C) and donor human (Fig 5, D) vagus.
E, Responses to GSK1016790A (300 nmol/L) were virtually abolished in Px12/2 mice. KO, Knockout; WT,
wild-type. F and G, Both GSK1016790A- and 280 mOsm–induced depolarization in guinea pig (Fig 5, F)
and donor human (Fig 5, G) vagus was inhibited by AF-353 (10 mmol/L) and TNP-ATP (10 mmol/L).
H, [Ca21]i signal induced by GSK1016790A (30 nmol/L) in the guinea pig airway–specific nodose ganglia
neurons was also inhibited by AF-353 (10 mmol/L; N 5 3; n 5 4). Data are presented as means 6 SEMs
of 4 to 6 observations for guinea pig and 2 to 3 observations for human experiments. *Statistical
significance (P < .05), unpaired t test comparing responses in Px12/2 vagus with wild-type control or
GSK1016790A-induced [Ca21]i responses in nodose neurons.
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n5 30) and nodose (N5 8, n5 32) neurons examined expressed
both b-actin and PGP9.5 (examples are shown in Fig E3 in this
article’s Online Repository at www.jacionline.org).
The effect of ab-methylene-ATP (ab-MeATP), a more stable
agonist at P2X1 and P2X3 receptors, on the activation of vagal
sensory nerves was examined to determinewhether ATP is able to
directly activate airway sensory nerves. ab-MeATP (10 mmol/L)
induced an increase in [Ca21]i levels predominantly in airway-
specific neurons from nodose ganglia in the guinea pig (Fig 5,
A) and was also able to cause a concentration-dependent depolar-
ization of the guinea pig vagus nerve (Fig 5, B). The agonist also
caused firing of Ad-fibers but had no effect on bronchospasm (see
Fig E4 in this article’s Online Repository at www.jacionline.org).This activation was shown to be specific to P2X3 because depo-
larization was inhibited with the P2X2 and P2X3 inhibitors
TNP-ATP32 (10 mmol/L) and AF-35333 (10 mmol/L) in both
guinea pig (Fig 5,C) and human (Fig 5,D) vagus, but these inhib-
itors did not block responses to capsaicin and acrolein (see Fig E5
in this article’s Online Repository at www.jacionline.org). Activa-
tion of TRPV4 has been hypothesized to cause ATP release and
subsequent activation of P2X3.34 Both inhibitors were also shown
to inhibit TRPV4-specific depolarization because TNP-ATP
(10 mmol/L) and AF-353 (10 mmol/L) inhibited depolarization
induced by GSK1016790A and hypo-osmotic (280 mOsm) solu-
tion in guinea pig (Fig 5, F) and human (Fig 5, G) vagus. In addi-
tion, depolarization induced by GSK1016790Awas abolished in
Px12/2 mice, whereas responses to ab-MeATP (10 mmol/L),
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unchanged, suggesting that TRPV4 is dependent on pannexin 1
to induce depolarization in the mouse (Fig 5, E). Furthermore,
AF-353 (10 mmol/L) significantly inhibited the [Ca21]i signal
induced by GSK1016790A (30 nmol/L) in airway-specific
neurons from nodose ganglia. Calcium responses, expressed as
a percentage of K50 signal (AUC), induced by GSK1016790A
(30 nmol/L) were significantly reduced from 93% 6 6.2% with
vehicle control to 28% 6 11.9% after incubation with AF-353
(Fig 5, H).Effect of P2X3 antagonists on activation of airway
sensory nerves by TRPV4 in vivo
For antagonist studies, only Ad-fibers were investigated. In all
cases citric acid activated the nerves under investigation and was
used as an initial test for nerve fiber viability. To investigate the
role of the P2X3 antagonist AF-353 on Ad firing induced by
abMe-ATP, GSK1016790A, and hypo-osmotic solution,
Ad-fibers (n 5 12) were investigated, with CVs ranging from
3.8 to 14.1 m/s. After vehicle administration (example trace is
available in Fig E6, A, in this article’s Online Repository at www.
jacionline.org), total impulses induced after aerosol administra-
tion of the P2X1/3 agonist ab-MeATP (300 mmol/L) remained
unchanged from 177.0 6 64.73 impulses before vehicle
administration to 236.0 6 79.38 impulses afterward (Fig 6, A).
Total impulses induced by GSK1016790A (100 ng/mL) after
vehicle were 346 6 114.9 (Fig 6, A). After administration of
the P2X3 antagonist AF-353 (30 mg/kg; example trace is
available in Fig E6, B), total impulses induced by the P2X1/3
agonist ab-MeATP (300 mmol/L) was significantly reduced
from 151.0 6 18.36 to 12 6 4.51 impulses, and GSK1016790A
firing was also significantly reduced to 22 6 10.44 impulses
compared with vehicle control (Fig 6, B, and see Fig E6, B). Total
impulses induced by hypo-osmotic solution were also
significantly inhibited after application of the P2X2/3 antagonist
AF-353, where total impulses were reduced from 247.0 6 15.37
to 83.67 6 20.92 after antagonist administration. Vehicle had
no effect on firing (Fig 6, C and D). Treatment with AF-353
(30 mg/kg administered intraperitoneally) had no effect on capsa-
icin (100 mmol/L)–induced firing (total impulses, 1506 58.01 to
209 6 40.53 after AF-353 administration; n 5 2).
The TRPV4 antagonist GSK2193874 was also investigated
against GSK1016790A-, abMe-ATP–, and hypo-osmotic
solution–induced firing of Ad-fibers. Ad-fibers (N 5 12) were
investigated, with CVs ranging from 3.2 to 14.3m/s. After vehicle
administration, the total number of impulses induced by the
TRPV4 agonist GSK1016790A (100 ng/mL) was unchanged
from 337.7 6 84.41 to 335 6 7.64 (Fig 6, E). The total number
of impulses induced by the P2X1/3 agonist abMe-ATP
(300 mmol/L) administered at the end of the experiment was
156.7 6 46.70 (Fig 6, E). After administration of the antagonist
GSK2193874 (300 mg/kg; example trace shown in Fig E6, C),
the total number of impulses induced by GSK1016790A
(100 ng/mL) was significantly reduced from 261.7 6 20.92
to 27.67 6 11.55 impulses (Fig 6, F). Firing induced by
abMe-ATP (300 mmol/L) remained unchanged at
182.3 6 20.30 impulses compared with vehicle control (Fig 6,
F). Similarly, the total number of impulses induced by hypo-
osmotic solution was significantly reduced from 219.3 6 58.46
to 71.67 6 16.13 (Fig 6, H). Vehicle had no effect on firing(Fig 6, G). Treatment with GSK2193874 (300 mg/kg
administered intraperitoneally) had no effect on capsaicin-
induced firing (ie, total impulses induced by capsaicin were not
significantly changed from 130 6 35.81 to 177 6 34.51 after
GSK2193874 administration; n 5 3).
Aerosolized GSK1016790A, but not vehicle, induced
concentration-related coughing in conscious unrestrained guinea
pigs (see Fig E7 in this article’s Online Repository at
www.jacionline.org). The type of coughs induced were a
combination of small tussive trains similar to those seen after
stimulation with prostaglandin E2 or bradykinin and large single
explosive coughs normally induced by agonists, such as acrolein
and capsaicin.21 HC067047 (100 mg/kg administered intraperito-
neally) significantly inhibited coughing induced by a submaximal
concentration of GSK1016790A agonist (3 mg/mL; Fig 6, I). An
alternate antagonist, GSK2193874 (300 mg/kg), also inhibited
the number of coughs induced by GSK1016790A (30 mg/mL;
6J). The P2X3 antagonist AF-353 (30 mg/kg administered intra-
peritoneally) inhibited cough induced by the GSK1016790A
(30 mg/mL) in the guinea pig to a level similar to that seen with
the TRPV4 antagonist (Fig 6, K). Neither AF-353 (30 mg/kg
administered intraperitoneally) nor GSK 2193874 (300 mg/kg
administered intraperitoneally) were shown to have any effect
on capsaicin (60 mmol/L; aerosolized for 5 minutes and coughs
counted for 10 minutes)–induced cough. Mean cough counts
were not significantly changed from 8.5 6 3.6 after intraperito-
neal vehicle administration versus 6.5 6 2.8 after GSK2193874
and 7.6 6 1.9 after AF-353 (n 5 8 in each group). Capsaicin-
induced cough using the same protocol has previously been
shown to be completely inhibited by a TRPV1 receptor
antagonist.21DISCUSSION
The sensory transduction mechanisms involved in regulating
reflexes in response to changes in airway osmolarity are not
known. TRPV4 has previously been shown to be an osmosen-
sor12,13 and is widely expressed in the respiratory tract.14-17,35
However, not much is known regarding the role of TRPV4 as a
peripheral nociceptor in the airway.
To investigate this, we used the guinea pig as a model species
because it is widely used for investigations into airway sensory
nerve biology and because guinea pigs cough in a similar fashion
to human subjects in response to a range of tussive agents.3-5
In the present study we investigated TRPV4 expression in
peripheral nociceptive neurons and in particular those that
innervate the lung. Although TRPV4 expression has previously
been demonstrated in peripheral sensory nerves with cell bodies
located in the trigeminal ganglia36 and dorsal root ganglia,37 it has
not been identified in neurons from the vagal ganglia. To assess
the airway-specific effects of TRPV4 stimulation, we used
fluorescent imaging in isolated guinea pig vagal ganglia neurons,
whichwere labeled with the retrograde tracer DiI. GSK1016790A
(TRPV4 agonist) induced concentration-dependent increases in
[Ca21]i levels in nodose but not jugular neurons, and
GSK1016790A, 4a-PDD, and hypo-osmotic solution induced
depolarization of guinea pig, mouse, and human vagal sensory
nerves. These effects were inhibited by the TRPV4 antagonists
and reduced in vagus from Trpv42/2mice (acrolein and capsaicin
responses were unaffected). Confirming the activity on airway-
specific afferents, we used in vivo single-fiber electrophysiologic
FIG 6. A-D, Effect of vehicle (10% PEG in saline, 10mL/kg administered intraperitoneally) or AF-353 (30mg/kg
administered intraperitoneally) on firing of Ad-fibers induced by ab-MeATP (aerosolized at 300 mmol/L for
1minute; shown inFig6,A andB, respectively) or hypo-osmotic solution (280mOsmaerosolized for 1minute;
Fig 6, C and D). E-H, Effect of vehicle (6% Cavitron in saline, 10 mL/kg administered intraperitoneally) or
GSK2193874 (300 mg/kg administered intraperitoneally) on firing of Ad-fibers induced by GSK1016790A
(aerosolized at 100 ng/mL for 1minute) or ab-MeATP or hypo-osmotic solution (all n5 3). I-K, Effect of vehicle,
TRPV4 (HC067047, 100 mg/kg; GSK2193874, 300 mg/kg administered intraperitoneally), or P2X3 (AF-353,
30 mg/kg administered intraperitoneally) antagonists on cough induced by the TRPV4 agonist
GSK1016790A (30 mg/mL, aerosolized for 5 minutes) is shown, and coughs were counted for 10 minutes.
Data were expressed as means 6 SEMs. *Statistical significance (P < .05) compared with relevant control
(n5 8-12). #Statistical significance (P < .05) comparing GSK1016790A to vehicle control.
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hypo-osmotic solution caused a marked prolonged stimulation
of all of the Ad-fibers examined (both capsaicin-sensitive and
insensitive fibers) but had no effect on the C-fibers. This is in
contrast to a previous study in which TRPV4 and hypo-osmolar
solutions activated saphenous nerve C-fibers in the rat.13 It is
not clear why we did not see a similar profile of C-fiber activation,
but perhaps anatomically distinct afferent nerve fibers and
different species account for this difference. In addition,
although the activation of Ad-fibers was relatively short lived
after capsaicin and citric acid, the fibers were still firing
vigorously at 30 minutes after GSK1016790A administration.
GSK1016790A also caused marked bronchoconstriction with a
slow onset and prolonged duration that ensued after the Ad-fibers
had been activated. Although the bronchospasm occurred after
the initiation of fiber firing, we cannot rule out the possibility
that firing of Ad-fibers was secondary to bronchospasm. However,
the fact that GSK1016790A evoked compound depolarization of
the vagus nerve and increased the [Ca21]i signal in the vagal
ganglia, which are systems free from the influence of broncho-
spasm, suggests that the firing is independent of bronchospasm.
Furthermore, aerosolized GSK1016790A induced cough in
conscious unrestrained guinea pigs, which was inhibited by
both TRPV4 antagonists (HC067047 and GSK2193874).
It has previously been reported that TRPV4 regulates urothelial
ATP release to modulate mechanosensitive bladder afferent
nerves.34,38 Furthermore, TRPV4 has been shown to release
ATP from human airway macrophages and epithelial cells.17 In
these studies we have established a role for ATP and the P2X3
receptor in TRPV4-mediated activation of airway afferents. We
have demonstrated expression of P2X3 and P2X2, and
ab-MeATP caused a [Ca21]i level increase in guinea pig nodose
ganglion neurons, which is in agreement with previous
studies.23,39 ab-MeATP was also able to depolarize guinea pig
and human vagus nerves, and both the increase in calcium levels
and the vagal depolarization evoked by ab-MeATP were
inhibited by the P2X1 and P2X3 inhibitor TNP-ATP and the
P2X3 inhibitor AF-353. Both inhibitors were also shown to
inhibit depolarization induced by TRPV4 ligands and
hypo-osmotic solution in guinea pig and human vagus,
confirming the hypothesis that TRPV4- and hypotonicity-
mediated activation of vagal afferents is mediated by the release
of ATP and activation of P2X3 receptors. In vivo single-fiber
recording experiments were performed to confirm the role of
ATP/P2X3 in the TRPV4- and hypotonicity-induced activation
of Ad airway-specific afferents. Unlike the activation of Ad-fibers
observed with capsaicin and citric acid, which occurred rapidly,
activation caused by GSK1016790A was relatively slow, which
indicated an indirect mechanism of action. This firing was
inhibited after administration of the TRPV4 antagonist
GSK2193874. In addition, the P2X3 antagonist AF-353
decreased the firing frequency to ab-MeATP and
GSK1016790A. Furthermore, the P2X3 antagonist AF-353
inhibited cough induced by GSK1016790A in the guinea pig to
a similar level to that observed with the TRPV4 antagonist. These
studies have identified the TRPV4-ATP-P2X3 axis as a key driver
of hypotonicity-induced activation of airway afferents. Although
the TRPV4 and P2X3 receptor antagonists inhibited the majority
of the response to hypotonicity in most of the systems used, the
small residual response might be mediated by an alternative
mechanism.It is not clear what mechanisms are important in TRPV4-
induced ATP release. Interestingly, 2 recent studies in human
epithelial cells have suggested that TRPV4 plays a role in the
release of ATP and that this is associated with opening of the
pannexin 1 channel.17,19 Studies were performed in vagus ob-
tained from pannexin knockout (Px12/2) and wild-type mice to
further investigate the signaling mechanism. The TRPV4 agonist
response was absent in Px12/2 mice, whereas responses to
ab-MeATP, capsaicin, and acrolein remained unchanged,
suggesting that TRPV4 is dependent on activation of the pannexin
1 pore and subsequent release of ATP to induce depolarization in
the mouse vagus. It is also not certain what cell type is important
in TRPV4-induced ATP release in vivo. However, in single-cell
PCR studies we only demonstrated TRPV4 expression in 1 of
32 nodose ganglion neurons, suggesting that although TRPV4
can release ATP fromneuronal cells, it is more likely to be coming
from an alternative cell type in close proximity. Furthermore,
TRPV4 expression has been demonstrated in neuron-associated
cells (eg, glia40), and in our studies, in some cases, an accessory
or satellite cell was observed in close proximity to the DiI neuron
being imaged (Fig 1, A and B). In addition, TRPV4 can also
induce ATP release from several diverse cell types in the airway
(eg, epithelial cells and macrophages17), and therefore other
sources of ATP cannot be ruled out in the in vivo situation.
Interestingly, TRPV4 is expressed on airway smooth muscle,
and we and others have shown that it causes bronchospasm,15
which could theoretically lead to indirect activation of Ad-fibers,
action potential generation, and cough. However, these data do
not suggest that bronchospasm per se activates Ad-fibers given
that the effect is also inhibited by the P2X3 antagonist and
P2X3 is almost exclusively expressed on sensory nerves.
However, it is still possible that TRPV4-induced bronchocon-
striction could be responsible for ATP release, which then leads
to Ad-fiber activation. However, it is also possible that TRPV4
might elicit ATP release from other cell types (eg, macrophages
and epithelial cells) in the appropriate location independent of
bronchospasm.
Another interesting finding from this study was the absence
of TRPV4-ATP–mediated effects on C-fibers, providing a
distinct neurobiology for this target compared with TRPV1/
TRPA1, although it is acknowledged that ATP can directly
activate both C-fibers and Ad-fibers independent of TRPV4
activation. This work is of particular interest given recent data
suggesting that the P2X3 receptor antagonist AF-219 inhibited
cough frequency in patients with refractory chronic cough, an
effect for which these studies might provide a potential
mechanistic explanation.41 It is not yet clear whether chronic
cough in other patient groups involves release of ATP and
activation of P2X3 receptors and whether this would happen
in a TRPV4-dependent manner.
Chronic cough is associated with many respiratory diseases
(eg, asthma, COPD, pulmonary fibrosis, bronchiectasis, and lung
cancer) in addition to refractory chronic cough.42 Increased levels
of extracellular ATP have been reported in the airways of
asthmatic patients and patients with COPD,43,44 and
polymorphisms in the TRPV4 gene have been associated with
COPD phenotypes,18 suggesting there might be some rationale
for this mechanism being operative in cough associated with
asthma and COPD. Current treatment options for chronic cough
are limited, and a recent systematic review concluded that
over-the-counter remedies lack evidence of effectiveness.45
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with a family doctor or a general or respiratory physician.46
Despite these facts, cough is a largely ignored research area,
and novel antitussive agents are required.
In summary, this study has identified the TRPV4-ATP axis as
the key osmosensor involved in initiation of airway sensory nerve
reflexes. The absence of TRPV4-ATP–mediated effects on
C-fibers provides a distinct neurobiology for this target compared
with TRPV1/TRPA1 and as such presents a distinct target for
possible antitussive therapies. It is not clear whether TRPV4
antagonists will be more or less effective than TRPV1 or TRPA1
antagonists or whether they will address different cough pheno-
types. However, human tussive challenge studies might shed
more light on this question if certain patient groups respond more
to some tussive agents rather than others (eg, hypo-osmolar
solutions indicative of TRPV4-driven cough hypersensitivity vs
capsaicin, which is indicative of TRPV1). The effectiveness of the
P2X3 antagonist (AF-219) in patients with chronic idiopathic
cough might suggest that TRPV4 could be an effective alternative
therapy in this patient group, although we await clinical trials to
support or reject this hypothesis.
Homozygous breeding pairs of mice genetically modified to disrupt the
TRPV4 gene (Trpv42/2; RBRC no. 01939) were obtained from Riken
BioResource Center (Tsukuba, Japan). Mice devoid of the pannexin 1 gene
(Px12/2) were a kind gift from Dr Vishva Dixit (Genentech, South
San Francisco, Calif). The TRPV4 antagonist GSK2193874 was a kind gift
from Almirall (Barcelona, Spain), and the P2X3 inhibitor AF-353 was kindly
provided by Afferent Pharmaceuticals (San Mateo, Calif).
Key messages
d Inhalation of hypo-osmolar solutions provokes broncho-
spasm and cough in asthmatic patients, but the mecha-
nisms involved are unknown.
d For the first time, we have identified the TRPV4-ATP-
P2X3 axis as a key osmosensor expressed on Ad nocicep-
tors but not on C-fiber afferents, providing a distinct
neurobiology for this channel compared with TRPV1
and TRPA1.
d These observations are of therapeutic importance given
data reported from a recent clinical study that showed
an unprecedented effect of a P2X3 receptor antagonist
on daytime cough rate and cough severity in patients
with treatment-resistant chronic cough.
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Animals
Male Dunkin-Hartley guinea pigs (300-500 g; 400-800 g for single-fiber
in vivo studies) and C57BL/6 mice (18-20 g) were purchased fromHarlan (Bi-
cester, Oxon, United Kingdom) and housed in temperature-controlled (218C)
rooms with food and water freely available for at least 1 week before
commencing experimentation. Homozygous breeding pairs of mice geneti-
cally modified to disrupt the TRPV4 gene (Trpv42/2; RBRC no. 01939)
were obtained from Riken BioResource Center (Tsukuba, Japan).E1,E2 Mice
devoid of the pannexin 1 gene (Px12/2)were a kind gift from Dr Vishva Dixit
(Genentech). Experiments were performed in accordance with the UK Home
Office guidelines for animal welfare based on the Animals (Scientific Proce-
dures) Act of 1986 and the ARRIVE guidelines.E3
Isolated primary vagal ganglia
Cell dissociation. Guinea pigs were killed by means of injection of
sodiumpentobarbitone (200mg/kg administered intraperitoneally). Nodose and
jugular gangliawere dissected free of adhering connective tissue and isolated by
means of enzymatic digestion, as described previously.E4,E5 Briefly, nodose and
jugular ganglia were separated and incubated with activated papain solution
(Sigma, St Louis, Mo; papain type, 200 U/mL in Ca21- and Mg21-free
HBSS) for 30 minutes at 378C, followed by incubation for 40 minutes with
type 4 collagenase (2 mg/mL; Worthington Biochemical, Lakewood, NJ) and
Dispase II (2.4 mg/mL; Roche, Mannheim, Germany). Neurons were
dissociated by means of trituration with fire-polished glass Pasteur pipettes
andwashed by using centrifugation. The supernatantwas decanted and the pellet
was carefully homogenized inHBSS at room temperature. Cells were separated
from the remaining tissue by means of centrifugation in L-15 medium
containing 20% Percoll (vol/vol), followed by washing with L-15 medium
alone. Cells were resuspended in complete F-12 medium and plated in
poly-D-lysine/laminin (22.5 mg/mL)–coated FluoroDishes (World Precision
Instruments, Hertfordshire, United Kingdom). Neurons were allowed to adhere
for 2 hours and then gently flooded with complete F12 medium (10% FBS,
10,000 U/mL 1% penicillin, and 10 mg/mL streptomycin). Plates were used
for experimentation within 24 hours.
[Ca21]i measurements were performed in dissociated nodose and jugular
neurons. Neurons projecting fibers specifically to the airways were identified
by using the retrograde tracer DiI (1 mL/kg administered intranasally) dosed
14 to 28 days before neuron isolation to allow time for the dye to travel from
the nerve endings to the cell bodies.
Calcium imaging. Fluorodishes were loaded with Fura-2 AM
(3 mmol/L; Invitrogen, Carlsbad, Calif) for 40 minutes in the dark at 258C
and allowed to de-esterify for 30 minutes in the dark at 258C. After washing, a
fluorodish was placed in a full incubation chamber mounted on the stage of a
Widefield inverted microscope and imaged at excitation and emission
fluorescence wavelength l values of approximately 520 to 550 nm and
570 nm, respectively, to identify DiI-labeled cells. [Ca21]i signals were re-
corded, as described previously.E4,E5 Briefly, neurons were constantly super-
fused with ECS buffer by using an in-house pressurized solution-changing
perfusion system, allowing complete bath (600-mL volume) replacement in
3 seconds. Before experiments, the cells were superfused for 10 minutes
with ECS only. K50 (50 mmol/L potassium solution as opposed to
5.4 mmol/L used in Krebs solution or ECS) was applied at the start of each
experiment for 10 seconds to assess cell viability and normalize responses.
The 50 mmol/L solution is made by substituting potassium for sodium (ie, po-
tassium content increased by 43.6 mmol/L and sodium content decreased by
the same amount to prevent an osmotic effect). For experiments involving
the selective TRPV4 agonist GSK1016790A, after washout of K50, a solution
of GSK1016790A agonist (10-300 nmol/L) or vehicle (0.1% dimethyl sulf-
oxide [DMSO] vol/vol in ECS) was applied for 10 minutes. For experiments
involving P2X3 ligands, after K50 washout, a solution of the stable ATP
analogue ab-MeATP (10 mmol/L) or vehicle (0.1% dH20 vol/vol in ECS)
was applied for 10 minutes. For antagonist experiments, the P2X3 antagonist
AF-353 (10mmol/L) was incubated with the cells for 10 minutes before appli-
cation of GSK1016790A (30 nmol/L). One concentration of GSK1016790A
or ab-MeATPwas tested per plate. The concentration-response data representan overview of responding cells only. The criteria for a ‘‘responsive cell’’ were
judged to be an increase in [Ca21]i levels of 10% or greater of the response to
K50.
E4 In each caseN is defined as the number of animals and n is defined as the
number of cells tested. Only neurons producing a fast response to K50, which
was washable within 5 minutes, and with a diameter of greater than 20 mm
were analyzed (N 5 4-6 animals, n 5 5-27 cells per concentration).
Single-cell RT-PCR. The following protocol for RT-PCR of targets
in single neurons was carried out based on the methodology described by
Kwong et al.E6 Isolated nodose-derived neurons were placed in a Petri dish
containing ECS solution, and airway terminating (DiI-stained) neurons were
identified by using a Widefield Microscope (Olympus IX-71 inverted micro-
scope). Selected individual neurons were carefully harvested by using suction
into the end of a custom-made pulled-glass micropipette (tip ID, 50-70 mm;
OD, 2 mm; FIVEphoton Biochemicals) manipulated into place with a
micromanipulator (Three-axis Water Hydraulic Micromanipulator MHW3,
Narishige). The micropipette tip was then broken into a microreaction tube
containing 1 mL of RNaseOUT (Life Technologies) and placed on ice. Cells
were processed by using the Superscript III Direct cDNA Synthesis Kit
(Life Technologies) and Random Hexamers (Applied Biosystems) per the
manufacturer’s instructions and as described by Lieu et al.E7 Some sample
was removed immediately before addition of Superscript III reverse transcrip-
tase to be used as 2reverse transcriptase (RT) controls. Sample cDNA and
2RT controls were stored at2208C until PCR analysis. The reaction mixture
for PCR contained 0.5 U of HotStarTaqDNAPolymerase, 2.5mmol/LMgCl2,
and PCR buffer (HotStarTaq Polymerase; Qiagen, Hilden, Germany), as well
as 200 mmol/L dNTP and custom-synthesized intron-spanning primers
(0.5 mmol/L each of forward/reverse primer). The PCR reaction conditions
were activation at 958C for 15 minutes and then 50 cycles of denaturation at
948C for 30 seconds, annealing at 608C for 30 seconds, and extension at
728C for 1 minute, followed by a final extension at 728C for 10 minutes.
TRPV4, P2X3, and PGP9.5 primers were designed with the Primer-BLAST
Primer Designer Tool from the National Center for Biotechnology
Information (NCBI; http://www.ncbi.nlm.nih.gov/tools/primer-blast/), and
b-actin and P2X2 primers were from Lieu et alE8 and Kwong et al,E6
respectively. PCR products were separated by means of electrophoresis on
1.5% agarose gels. Data presented here are from samples in which 2RT
controls produced no product and additionally in which both a specific product
was amplified in b-actin and PGP9.5 primer reactions, indicating successful
picking of a neuronal cell.
Primer design. TRPV4, P2X3, and PGP9.5 primers were custom
designed by using the NCBI’s Primer-BLAST Web site and selected, where
possible, to span an exon-exon junction (TRPV4 and PGP9.5) or to be
positioned on separate exons (intron spanning, P2X3). The NCBI nucleotide
database contains 5 predicted TRPV4 mRNA variants: our primers were
designed to target all of the potential isoforms to ensure we found any TRPV4
expressed in the single cells. Primer sequences and accession numbers or
literature references used for primer design are presented in Table E1. All
primers were ordered fromLife Technologies. Representative examples of elec-
trophoresis gels for PCR products generated by TRPV4, P2X3, and P2X2
primers in separate jugular- and nodose-derived neurons are shown in Fig E3.
Isolated vagus nerve preparation
Guinea pigs and mice (C57BL/6 or Trpv42/2)E1,E2 were killed bymeans of
injection of sodium pentobarbitone (200 mg/kg administered intraperitone-
ally). The vagus nerves were removed, and experiments were conducted in a
fully characterized isolated vagal preparation, as described in previous publi-
cations.E9,E10 Human vagus nerves (n5 6, 38- to 57-year-old male donors and
38- to 68-year-old female donors with no known respiratory disease) were ob-
tained from the International Institute for the Advancement of Medicine (Edi-
son, NJ). In all cases the tissuewas consented for use in scientific research, and
ethics approval was obtained from the Royal Brompton & Harefield Trust.
Noncumulative concentrations of the selective TRPV4 agonists
GSK1016790A (0.03-1 mmol/L) or 4a-PDD (0.3-10 mmol/L) or the
endogenous stimulus hypo-osmotic solution (0 to2100 mOsm below normal
airway osmolarity of 297 mOsm) were applied in a random order for
2 minutes, followed by a wash period with Krebs solution to restore baseline
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doses of GSK1016790A (300 nmol/L), 1 mmol/L 4a-PDD (1 mmol/L), and
hypo-osmotic solution (280 mOsm) were chosen and subsequently used for
inhibitor studies. The ability of all agonists to stimulate human vagus
nerve was also determined (n 5 3). Concentration responses for the
TRPV4-selective inhibitors HC067047 and GSK2193874 or vehicle (0.1%
DMSO vol/vol in Krebs solution) were established against both
GSK1016790A and 4a-PDD in guinea pig and, for HC067047, in wild-type
mouse vagus nerve (n 5 4). From this, the dose of antagonist exhibiting
maximal inhibition (10 mmol/L) was chosen for further experiments.
We confirmed data generated with pharmacologic tools by using tissues
from Trpv42/2 vagal knockout mice (n5 4). Knockdown of the TRPV4 gene
was confirmed by using standard genotyping techniques. Subsequently,
TRPA1-selective (HC-030031; 10 mmol/L) and TRPV1-selective
(JNJ17203212; 100 mmol/L) antagonists were tested against GSK1016790A
and 4a-PDD on both guinea pig and mouse vagus (n 5 4). In addition,
HC067047 (10 mmol/L) was tested against acrolein (300 mmol/L)– and
capsaicin (1 mmol/L)–induced vagus nerve depolarization to ensure that the
antagonist was not exhibiting off-target effects on the TRPA1 or TRPV1
receptors (n 5 4, see Fig E2). Vehicle for all antagonists was 0.1% DMSO
vol/vol in Krebs solution. Effective concentrations for the TRPA1 and
TRPV1 tools had been previously established in our laboratory.E4
To investigate potential mechanisms of TRPV4-mediated activation of
airway sensory nerves, an initial concentration response to ab-MeATP
(0.1-300 mmol/L), a stable agonist at P2X1 and P2X3 receptors, was carried
out in guinea pig tissue, and a submaximal concentration was taken forward
for inhibitor studies (100 mmol/L). Specificity of the agonist for its receptor
was determined by using the P2X2/P2X3 antagonist TNP-ATP (10 mmol/L)
and the P2X3 antagonist AF-353 (10 mmol/L). These antagonists were then
tested against GSK1016790A-induced depolarization alongside capsaicin-
and acrolein-induced depolarization. Vehicle for the antagonists was 0.1%
DMSO vol/vol in Krebs solution.
In vivo single-fiber preparation
Guinea pigs were anesthetized with urethane (1.5 g $ kg21) intraperitone-
ally. If required, anesthesia was supplemented with additional urethane. The
trachea was cannulated with a short length of Portex tubing, and blood gases
and pH were maintained at physiologic levels by using artificial ventilation
(Ugo Basile small-animal ventilator) with a tidal volume of 10 mL $ kg21
and 50 to 60 breaths $ min21 of laboratory air. The right jugular vein and ca-
rotid artery (passed to the ascending aorta/aortic arch) were cannulated for in-
jecting drugs and measuring systemic arterial blood pressure, respectively.
Systemic arterial blood pressure and heart rate were continuously recorded
with a transducer (Gould P23XL). Tracheal pressure was measured with an
air pressure transducer (SenSym 647) connected to a side arm of the tracheal
cannula. Body temperature was continuously monitored with a rectal
thermometer and maintained at 378C with a heated blanket and control unit
(Harvard Apparatus, Holliston, Mass). Animals were paralyzed with vecuro-
nium bromide, which was initially administered at a dose of 0.10 mg $ kg21
administered intravenously, followed every 20 minutes by 0.05 mg $ kg21
administered intravenously to maintain paralysis. The depth of anesthesia
was frequently assessed by monitoring the response of heart rate and blood
pressure to noxious stimuli. Both cervical vagus nerves were located through
a cervical incision and dissected free from the carotid artery and sympathetic
and aortic nerves; both vagus nerves were cut at the central end. The left vagus
nervewas used for sensory nerve fiber recording and cleared of its surrounding
fascia. The skin andmuscle in the neck at either side of the incision were lifted
and tied to a metal ring to form a well, which was filled with light mineral oil.
Bipolar Teflon-coated platinum electrodes (exposed at the tips) were used for
recording purposes by using fascia positioned on 1 electrode for a reference.
The vagus nerve was placed on a small black Perspex plate to facilitate
subsequent dissection. Thin filaments of nerve were teased from the vagus
nerve under a binocular microscope and placed on the second electrode until
a single active unit or one of not more than 2 or 3 units was obtained. Action
potentials were recorded in a conventional manner by using electrodes
connected to a pre-amp Headstage (Digitimer NL100K; Digitimer, Welwyn
Garden City, United Kingdom). The signal was amplified (31000-35000,Digitimer NL104), filtered (in the range of LF30Hz-HF8.5kHz, Digitimer
NL125), and passed through a HumBug noise reducer (AutoMate Scientific,
San Francisco, Calif) before input sampling and recording. All signals were
sampled (50 kHz) and recorded by using the Spike 2 software data acquisition
system (Cambridge Electronic Design, Cambridge, United Kingdom) through
a CED Micro1401 interface. The software allowed pulse train counting over
selected time periods. In addition, monitoring of the input signal to the Spike
softwarewas also carried out on a digital storage oscilloscope (Tektronix DPO
2012). The input signal was also fed through an audio amplifier to a
loudspeaker. All animals were killed at the end of the experiments with an
overdose of pentobarbitone.
CVs were measured to distinguish slow-conducting nonmyelinated
C-fibers from fast-conducting myelinated Ad-fibers by stimulating the vagus
nerve close to the thorax with bipolar silver electrodes by using a supra-
threshold voltage at 0.5 ms and 1 Hz (Grass stimulator; Grass Technologies,
Warwick, RI). The corresponding action potential was recorded in the nerve
fiber under observation. The stimulus and the recorded action potential were
captured on the Spike software in a single sweep, and the time interval
between them was measured to calculate the velocity by using the distance
from the cathode-stimulating electrode and the recording electrode. Aerosols
were generated by an Aerogen nebulizer (Buxco Nebulizer Control-5)
connected to the ventilator and arranged so that the inspired air passed
through the medication chamber before entering the lungs of anesthetized
animals through the tracheal cannula.
Single vagus nerve fibers were identified as originating from the major
groups of airway sensory nerve endings (ie, slowly adapting stretch receptors,
RARs, irritant receptors, and Ad-fibers, which were further subdivided into
those that were more acid and/or less capsaicin sensitive and with CVs slower
than conventional RARs) and pulmonary/bronchial C-fiber receptors by using
several criteria.E11 These include pattern of spontaneous discharge, response
to hyperinflation and deflation, adaptation indices, response to capsaicin/citric
acid administration, and CVs. As a rule, a receptor that had no obvious pattern
to the spontaneous activity (often very sparse), did not respond to
hyperinflation/hyperdeflation, but responded to capsaicin aerosol was pursued
as a C-fiber. Alternatively, and in the first instance, a receptor that had a
spontaneous discharge with a definite rhythmic respiratory pattern and
adapted rapidly/variably to hyperinflation/deflation was pursed as an Ad-fiber.
Finally, verification of fiber typewas confirmed at the end of the experiment by
determining the CV.
After surgery, animals were allowed to stabilize for at least 30 minutes. For
the TRPV4 agonist GSK1016790A, after identification of a lung-afferent
fiber, the ensuing protocol was pursued. After a control baseline recording of
at least 2 minutes, vehicle (1% ethanol plus 1% Tween 80 in saline) was
administered as an aerosol for up to 1 minute, and changes in fiber activity,
intratracheal pressure, and blood pressure were continuously recorded until
baseline or a steady state was re-established. After an interval of 20 minutes,
capsaicin (100mmol/L)was administered as an aerosol for 15 seconds, and the
changes in fiber activity, intratracheal pressure, and blood pressure were
continuously recorded until baseline or a steady state was re-established.
Citric acid (0.3 mol/L) was administered 20 minutes later as an aerosol for
1 minute, and variables were continuously recorded. After a further
20 minutes, GSK1016790A (10 mg $ mL21) was administered as an
aerosol for 1 minute, and the changes in fiber activity, intratracheal pressure,
and blood pressure were continuously recorded. When C-fibers were being
examined, capsaicin aerosol was repeated at least 30 minutes after
GSK1016790A.
In a separate series of experiments for hypo-osmotic solutions, a similar
protocol as for GSK1016790A was followed. After establishing responsive-
ness to capsaicin and citric acid, a 0-mOsm solution was administered for
1 minute as an aerosol, and variables were continuously recorded. After an
interval of 20 minutes, a hypo-osmotic solution of 280 mOsm was
administered as an aerosol for 1 minute, and the changes in fiber activity,
intratracheal pressure, and blood pressure were continuously recorded.
A 280-mOsm solution is a solution that is 80 mOsm less than the normal
airway osmolarity of2295mOsm.Thiswas achieved by reducing the chloride
concentration and gradual salt compensation with sucrose. The effect of a
low-chloride solution on sensory nerveswas circumvented by using amodified
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sucrose at the start of every experiment involving hypo-osmotic solution.
A similar protocol was followed for the set of experiments involving
ab-MeATP. After establishing responsiveness to capsaicin and citric acid,
ab-MeATP was administered as an aerosol into the airways for 1 minute, and
the changes in fiber activity, intratracheal pressure, and blood pressure were
continuously recorded. For antagonist experiments, only Ad-fibers were
investigated. Two control responses to 300 mmol/L abMe-ATP were carried
out 20 minutes apart, after which the antagonist or vehicle was administered
intraperitoneally (AF-353: 30mg/kg, vehicle: 10% polyethylene glycol 400 in
0.9% saline), to investigate the antagonist activity of the P2X3
antagonist AF-353. One hour later, ab-MeATP was reaerosolized into the
airways, and responses were monitored; 20 minutes later, GSK1016790A
(100 ng/mL) was readministered to the airways, and responses were
monitored. A similar protocol was undertaken for the TRPV4 antagonist
GSK2193874, where 2 control responses to GSK1016790A (100 ng/mL)were
carried out 20 minutes apart, after which antagonist or vehicle was
administered intraperitoneally (GSK2193874: 300 mg/kg, vehicle: 6%
Cavitron/2-hydroxypropyl-b-cyclodextrin in saline; Sigma-Aldrich, Poole,
United Kingdom). Changes in fiber activity, intratracheal pressure, and blood
pressure were continuously recorded throughout the experiment.
Conscious guinea pig cough model
In all experiments the operator was blind to the treatment group. Conscious
unrestrained guinea pigs were placed in individual plastic, transparent, whole-
body plethysmography chambers (Buxco), and cough was detected, as
previously described.E7,E8 A concentration response was initially established
for GSK1016790A (1-30 mg/mL) or appropriate vehicle (1% ethanol and 1%
Tween 80 in saline, n 5 4). The stimulus was aerosolized for 5 minutes, and
coughs were counted for 10 minutes by trained observers (2 in the room), who
were blind to the treatment group and counted the number of coughs, and a
mean of the 2 observer’s counts was taken as the final count. For the antagonist
studies, guinea pigs were injected intraperitoneally with HC067047 (100 mg/
kg) or appropriate vehicle (1% DMSO in 0.9% saline) 1 hour before exposure
to a submaximal concentration of aerosolized GSK1016790A (3 mg/mL).
A similar protocol was followed for the alternate TRPV4 antagonist
GSK2193874 (300 mg/kg; vehicle: 6% Cavitron/2-hydroxypropyl-b-cyclo-
dextrin in saline) and the P2X3 antagonist AF-353 (30 mg/kg; vehicle: 10%
polyethylene glycol in saline), which, in separate experiments, were injected
intraperitoneally 1 hour before aerosol administration of GSK1016790A
(30 mg/mL). GSK1016790A was aerosolized for 5 minutes, and the number
of coughs was counted for 10 minutes (n 5 12). A further cough study was
carried out, investigating the effect of AF-353 and GSK2193874 on
capsaicin-induced cough in conscious guinea pigs, to determine the specificity
of the antagonists. GSK2193874 (300 mg/kg; vehicle: 6% Cavitron/2-
hydroxypropyl-b-cyclodextrin in saline) and the P2X3 antagonist AF-353
(30 mg/kg; vehicle: 10% polyethylene glycol in saline) were injected intraper-
itoneally 1 hour before aerosol administration of the TRPV1 receptor agonist
capsaicin (60 mmol/L). Capsaicin was aerosolized for 5 minutes, and coughs
were counted for 10 minutes (n5 8). The dose of AF-353 selected for in vivo
experiments is consistent with previous in vivo studies.E12 The alternative
TRPV4 antagonist (GSK2193874) described by Thorneloe et alE13 was used
at 300 mg/kg, given that some effects of the TRPV4 agonist were not
completely inhibited at 30 mg/kg, at least in the rat.
Compounds and materials
The TRPV4 inhibitor HC067047 was purchased from Peakdale Molecular
(High Peak, United Kingdom), and GSK2193874 was a kind gift from
Almirall (Barcelona, Spain). The TRPA1 inhibitor HC030031 from Chem-
Bridge (San Diego, Calif) and 4a-PDD were purchased from LC Labs
(Woburn, Mass). AF-353 was a kind gift from Afferent Pharmaceuticals (San
Mateo, Calif), and TNPATP was purchased from Cayman (Ann Arbor, Mich).
All other agents were purchased from Sigma-Aldrich (Poole, Dorset, United
Kingdom).
Isolated vagal ganglia experiments. DiI was purchased
from Invitrogen (Molecular Probes) as solid crystals, which were then dilutedto a stock of 25 mg/mL in ethanol. A working solution (500 mg/mL in 0.9%
saline) was made fresh from the ethanol stock immediately before use. Fura-2
AM was purchased from Molecular Probes/Invitrogen. L-15 and HBSS were
purchased from Gibco/Invitrogen. The K50 solution contained 50 mmol/L
KCl, 91.4 mmol/L NaCl, 1 mmol/L MgCl2, 2.5 mmol/L CaCl2, 0.33 mmol/
L NaH2PO4, 10 mmol/L glucose, and 10 mmol/L HEPES, with pH adjusted
to 7.4 at 378C by using KOH. ECS buffer was made fresh on a daily basis
as follows: 5.4 mmol/L KCl, 136 mmol/L NaCl, 1 mmol/L MgCl2,
2.5 mmol/L CaCl2, 0.33 mmol/L NaH2PO4, 10 mmol/L glucose, and
10 mmol/L HEPES, with pH adjusted to 7.4 at 378C by using NaOH. All in-
hibitors were dissolved in 100% DMSO and diluted 1:1000 in ECS buffer to
the desired final concentrations.
In vitro vagus experiments. Krebs salts were obtained from
BDH (Dorset, United Kingdom), and Krebs-Henseleit solution was made
fresh on a daily basis (118 mmol/L NaCl, 5.9 mmol/L KCl, 1.2 mmol/L
MgSO4, 2.5 mmol/L CaCl2, 1.2 mmol/L NaH2PO4, 25.5 mmol/L NaHCO3,
and 5.6 mmol/L glucose). All inhibitors were dissolved in 100% DMSO
and diluted 1:1000 in Krebs buffer to the desired final concentrations. The
hypo-osmotic solution was made fresh on the day of the experiment by using
a modified Krebs-Henseleit solution with salt reduction, followed by gradual
compensation with sucrose. A solution of 197 mOsm (100 mOsm less than
normal airway osmolarity) contained 7 mmol/L KCl, 63 mmol/L NaCl,
1.2 mmol/L MgCl2, 1.2 mmol/L NaH2PO4, 5.6 mmol/L D-glucose,
25.5 mmol/L NaHCO3, and 2.5 mmol/L CaCl2. Solutions of increasing osmo-
larity were then made by addition of sucrose. For solutions of 217 mOsm
(280), 237 mOsm (260), 257 mOsm (240), 277 mOsm (220), and 297
mOsm (0), sucrose was added to the modified Krebs solution (280 mOsm:
20 mmol/L, 260 mOsm: 40 mmol/L, 240 mOsm: 60 mmol/L, 220 mOsm:
80 mmol/L, and 0 mOsm: 100 mmol/L). Because the chloride content of these
solutions is significantly reduced and therefore could have a functional effect,
the 0-mOsm solution was used both before and after application of the hypo-
osmotic solution. Osmolarity of the solutions was confirmed with a cryo-
osmometer (Osmomat030; Gonotec, Berlin, Germany).
In vivo cough and single-fiber experiments. Capsaicin
and GSK1016790A (Sigma-Aldrich) were dissolved in 1% ethanol and 1%
Tween 80 in 0.9% saline to a working solution. Citric acid was dissolved in
0.9% saline. abMe-ATP was dissolved in dH20 and 0.9% saline for a working
solution. HC067047 (100 mg/mL) was suspended in vehicle (1% DMSO in
0.9% saline), a total dosing volume of 10 mL/kg intraperitoneal
GSK2193874 (300 mg/kg) was suspended in vehicle (6% Cavitron/2-
gydroxypropyl-b-cyclodextrin in 0.9% saline), a total dosing volume of
30 mL/kg intraperitoneal AF-353 (30 mg/kg) was dissolved in vehicle (poly-
ethylene glycol 400 in 0.9% saline), and a total dosing volume of 1 mL/kg was
administered intraperitoneally.
Data analysis and statistics
The AUC of the calcium signal (calciumflux: total increase in calcium levels
to greater than resting level over time) was used to measure primary
neuron responses, which were normalized to calcium flux generated by
application of K50. Inhibition of agonist-induced responses was analyzed by
using an unpaired t test comparing the K50 percentage (AUC) with and without
antagonist. Data were analyzed for responding cells only, which were defined as
neurons with a response of 10% or greater of K50, and are presented as
means 6 SEMs, where N indicates the number of animals and n indicates the
number of cells.
Inhibition of agonist-induced responses in the isolated vagus nerve
preparation were analyzed by using the 2-tailed paired t test, comparing
responses to agonist in the absence and presence of antagonist in the same
piece of nerve. Data are presented as means 6 SEMs, with statistical
significance set at a P value of less than .05.
In the single-fiber experiments datawere analyzed by using the paired t test,
comparing responses (absolute values) after stimulus with baseline values
immediately preceding the response. Data are presented as means 6 SEMs,
with statistical significance set at a P value of less than .05.
Inhibition of fiber firing was analyzed by using the paired t test comparing
responses after antagonist with control values before antagonist
E6. Kwong K, Kollarik M, Nassenstein C, Ru F, Undem BJ. P2X2 receptors differ-
entiate placodal vs. neural crest C-fiber phenotypes innervating guinea pig lungs
and esophagus. Am J Physiol Lung Cell Mol Physiol 2008;295:L858-65.
E7. Lieu TM, Myers AC, Meeker S, Undem BJ. TRPV1 induction in airway vagal
low-threshold mechanosensory neurons by allergen challenge and neurotrophic
factors. Am J Physiol Lung Cell Mol Physiol 2012;302:L941-8.
E8. Lieu T, Kollarik M, Myers AC, Undem BJ. Neurotrophin and GDNF family ligand
receptor expression invagal sensory nerve subtypes innervating the adult guinea pig
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trol as appropriate. Statistical significance was set at a P value of less than .05.
Inhibition of cough by the TRPV4 antagonist or the P2X3 receptor
antagonist in vivo was analyzed by using the Mann-Whitney test comparing
responses from the antagonist group with those from the vehicle control.
Data are presented as means 6 SEMs, with statistical significance set at a P
value of less than .05.REFERENCES
E1. Suzuki M, Mizuno A, Kodaira K, Imai M. Impaired pressure sensation in mice
lacking TRPV4. J Biol Chem 2003;278:22664-8.
E2. Mizuno A, Matsumoton N, Imai M, Suzuki M. Impaired osmotic sensation in
mice lacking TRPV4. Am J Physiol Cell Physiol 2003;285:C96-101.
E3. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving biosci-
ence research reporting: the ARRIVE guidelines for reporting animal research.
PLoS Biol 2010;8:e1000412.
E4. Grace MS, Birrell MA, Dubuis E, Maher SA, Belvisi MG. Transient receptor po-
tential channels mediate the tussive response to prostaglandin E2 and bradykinin.
Thorax 2012;67:891-900.
E5. Dubuis E, Grace M, Wortley MA, Birrell MA, Belvisi MG. Harvesting, isolation,
and functional assessment of primary vagal ganglia cells. Cur Protoc Pharmacol
2013;62:Unit 12.15.
respiratory tract. Am J Physiol Lung Cell Mol Physiol 2011;300:L790-8.
E9. Maher SA, Birrell MA, Belvisi MG. Prostaglandin E2 mediates cough via the
EP3 receptor: implications for future disease therapy. Am J Respir Crit Care
Med 2009;180:923-8.
E10. Birrell MA, Belvisi MG, Grace M, Sadofsky L, Faruqi S, Hele DJ, et al. TRPA1
agonists evoke coughing in guinea pig and human volunteers. Am J Respir Crit
Care Med 2009;180:1042-7.
E11. Adcock JJ, Douglas GJ, Garabette M, Gascoigne M, Beatch G, Walker M, et al.
RSD931, a novel anti-tussive agent acting on airway sensory nerves. Br J Phar-
macol 2003;138:407-16.
E12. Munoz A, Somogyi GT, Boone TB, Ford AP, Smith CP. Modulation of bladder
afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and
P2X2/3 receptors. BJU Int 2012;110(8 Pt B):E409-14.
E13. Thorneloe KS, Cheung M, Bao W, Alsaid H, Lenhard S, Jian MY, et al. An orally
active TRPV4 channel blocker prevents and resolves pulmonary edema induced
by heart failure. Sci Transl Med 2012;4:159ra148.
FIG E1. Concentration-response curve of GSK2193874- against
GSK1016790A (300 nmol/L)–induced depolarization in the guinea pig
(N 5 4). *P > .05, t test comparing agonist and antagonist responses in
the same piece of nerve. V, Vehicle.
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FIG E2. A and B, Neither HC67047 (10 mmol/L; Fig E2, A) nor GSK2193874 (10 mmol/L; Fig E2, B) had any ef-
fect on TRPV1 (capsaicin)– or TRPA1 (acrolein)–induced depolarization in the guinea pig. C and D, A similar
result was seen in mouse vagus. Data are shown as means 6 SEMs of 3 to 6 observations.
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FIG E3. A, Representative examples of electrophoresis gels for PCR products generated by TRPV4 primers
in separate jugular- and nodose-derived neurons. TRPV4 was expressed in 0 of 30 jugular neurons and 1 of
32 nodose neurons. The positive control tissue for TRPV4 was the kidney. B, Representative examples
of electrophoresis gels for PCR products generated by P2X3 primers in separate jugular- and
nodose-derived neurons. P2X3 was expressed in 23 of 30 cells from the jugular and 17 of 32 cells from
the nodose ganglia. The positive control tissue for P2X3 was the trigeminal ganglia. C, Representative
examples of electrophoresis gels for PCR products generated by P2X3 primers in separate jugular- and
nodose-derived neurons. P2X2 was expressed in 1 of 30 jugular neurons and 13 of 32 of nodose neurons.
All cells analyzed expressed both PGP9.5 and b-actin. 1, Positive control; J, jugular-derived neurons;
L, ladder; N, nodose-derived neurons; W, water control.
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FIG E4. Example trace from an Ad-fiber where the top panel indicates
tracheal pressure (cm H2O) and the bottom panel indicates single-fiber
firing. ab-MeATP (300 mmol/L) caused firing in Ad-fibers but had no effect
on bronchoconstriction.
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FIG E5. Neither AF-353 (10 mmol/L) nor TNPATP (10 mmol/L) had any effect on capsaicin (A and B)– or acro-
lein (C and D)–induced depolarization in guinea pig vagus. Data are shown as means 6 SEMs of n 5 3 to 6
observations.
J ALLERGY CLIN IMMUNOL
JULY 2016
261.e9 BONVINI ET AL
FIG E6. A, Example vehicle trace. After 2 reproducible responses to ab-MeATP, vehicle (saline in 10%
PEG400) was administered, and the following nerve responses to ab-MeATP or GSK1016790A remained
unaffected. B, Conversely, after AF-353 administration, ab-MeATP response was significantly reduced, as
was the response to GSK1016790A compared with vehicle control. C, Example trace after GSK2193874
administration where nerve firing to GSK1016790A was reduced; however, there was no effect on
ab-MeATP–induced firing.
J ALLERGY CLIN IMMUNOL
VOLUME 138, NUMBER 1
BONVINI ET AL 261.e10
FIG E7. Aerosol of GSK1016790A caused a concentration-dependent
increase in the number of coughs in the conscious guinea pig. Vehicle
had no effect on coughing. Data are shown as means 6 SEMs of 4
observations.
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TABLE E1. Single-cell PCR primer information: list of primer sequences, product sizes, and coding DNA sequence accession ID/
references
Target Accession ID/reference Forward primer sequence (59-39) Reverse primer sequence (59-39) Size
b-Actin Lieu et alE8 TGGCTACAGTTTCACCACCA GGAAGGAGGGCTGGAAGA 212
TRPV4 XM_003477912.2 TGGGCAAGAACTCAGATGGC TCCACAGTCCTAGAGGGGAG 335
P2X2 Kwong et alE6 GCTGCTCATCCTGCTCTACTTT GGGCTTCACATACTCCTCCAC 157
P2X3 XM_003464224.1 AGGGAGGCTGAGAACTTCAC CAGCCAATCTTGATGCCCAG 239
PGP9.5 XM_003471552.2 GCCAGTGTCGGGTAGATGAC CGTGTGTGCAGAACCAAAGG 349
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